Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part I: Clinical and histologic features and diagnosis.
CD30(+) lymphoproliferative disorders
Sézary syndrome
T-cell lymphoma
adult T-cell leukemia
adult T-cell lymphoma
angioimmunoblastic T-cell lymphoma
cutaneous T-cell lymphoma
cytotoxic primary cutaneous anaplastic large cell lymphoma
extranodal NK/T-cell lymphoma
lymphomatoid papulosis
mycosis fungoides
nasal type
not otherwise specified
peripheral T-cell lymphoma
primary cutaneous CD4(+) small/medium T-cell lymphoproliferative disorder
primary cutaneous CD8(+) aggressive epidermotropic cytotoxic T-cell lymphoma
primary cutaneous acral CD8(+) T-cell lymphoma
primary cutaneous gamma-delta T-cell lymphoma
subcutaneous panniculitis-like T-cell lymphoma
Journal
Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
01
02
2021
revised:
12
04
2021
accepted:
26
04
2021
pubmed:
4
5
2021
medline:
19
3
2022
entrez:
3
5
2021
Statut:
ppublish
Résumé
Primary cutaneous T-cell lymphomas (CTCLs) are defined as lymphomas with a T-cell phenotype that present in the skin without evidence of systemic or extracutaneous disease at initial presentation. CTCLs other than mycosis fungoides and Sézary syndrome (SS) account for approximately one third of CTCLs and encompass a heterogenous group of non-Hodgkin lymphomas, ranging from indolent lymphoproliferative disorders to aggressive malignancies with a poor prognosis. The spectrum of CTCLs continues to broaden as new provisional entities are classified. Given the morphologic and histologic overlap among CTCLs and other diagnoses, a thorough clinical history, physical evaluation, and clinicopathologic correlation are essential in the work up and diagnosis of these rare entities. This article will summarize the epidemiologic, clinical, pathologic, and diagnostic features of CTCLs other than mycosis fungoides and SS.
Identifiants
pubmed: 33940098
pii: S0190-9622(21)00926-9
doi: 10.1016/j.jaad.2021.04.080
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1073-1090Informations de copyright
Copyright © 2021 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest Dr Noor is on the Advisory Board for Kyowa Kirin. Dr Horowitz is a consultant for Janssen, Kura Oncology, Myeloid Therapeutics, Vividion Therapeutics, and C4 Therapeutics; a Principal Investigator for Daiichi Sankyo, Portola Pharmaceuticals, Forty Seven Inc, Trillium Therapeutics, and Aileron; and a Principal Investigator and consultant for Kyowa Kirin, Celgene, Seattle Genetics, Verastem, Takeda, and ADC Therapeutics. Dr Moskowitz is a consultant for Imbrium Therapeutics LP; a Principal Investigator for Miragen, Incyte, Bristol-Myers Squibb; and a Principal Investigator and consultant for Merck and Seattle Genetics. Authors Stoll and Oh and Drs Pulitzer, Willner, and Myskowski have no conflicts of interests to declare.